Navigation Links
Study Redefines Placebo Effect as Part of Effective Treatment
Date:12/22/2009

It's not Drug or Placebo; It's Drug and Placebo

ROCHESTER, N.Y., Dec. 22 /PRNewswire-USNewswire/ -- Researchers used the placebo effect to successfully treat psoriasis patients with one quarter to one half of their usual dose of a widely used steroid medication, according to an early study published online today in the journal Psychosomatic Medicine. Early results in human patients suggest that the new technique could improve treatment for several chronic diseases that involve mental state or the immune system, including asthma, multiple sclerosis and chronic pain.

By designing treatment regimens that mix active drug and placebo, researchers at the University of Rochester Medical Center hope to maximize drug benefits, reduce side effects, increase the number of patients who take their medicine and extend the use of drugs otherwise limited by addiction risk or toxicity. Using a fraction of the usual drug dose to get the same effect could also make possible a dramatic and timely reduction in healthcare costs, according to the authors.

The publication is a product of decades of research in the emerging field of "psychoneuro-immunology," which holds that the ability of the human immune system to fight disease is closely linked with a person's mind. Thoughts and moods are captured in neurochemicals that cause the release of hormones which interact with disease-fighting cells.

The current research team chose psoriasis for their first human experiments because it is chronic, gets worse when patients feel stress and involves the immune system. The condition causes pain and disability in four million Americans as inherited traits and irritants cause the immune system to trigger the too fast production of skin cells, resulting in red, scaly patches of dead skin.

"Our study provides evidence that the placebo effect can make possible the treatment of psoriasis with an amount of drug that sh
'/>"/>

SOURCE University of Rochester Medical Center
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders
2. New Clinical Study Finds Masimo Perfusion Index (PI) Predicts Low Systemic Blood Flow in Preterm Infants
3. Express Scripts Study Finds No Association Between Anti-Epileptic Drug Switches and Increased Seizure Activity
4. First Patient Treated in Clinical Study of Cohera Medicals TissuGlu(R) Surgical Adhesive
5. Advanced Life Sciences Restanza Shows 100% Survival in Tularemia Pivotal Animal Study
6. Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study
7. Kristalose(R) Preferred by Patients With Chronic Constipation Compared to Similar Products in a Recent Study
8. Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study
9. GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer
10. Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy
11. Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014 Soligenix, ... late-stage biopharmaceutical company developing products that address unmet ... and biodefense, announced today that on December 24, ... offering. The Company raised approximately $2.3 ... intends to use the net proceeds from the ...
(Date:12/24/2014)... and FARMINGTON, Conn. ... Inc. (NYSE MKT: PTN), a biopharmaceutical company developing ... diseases with significant unmet medical need and commercial ... a private placement of 2,050,000 shares of its ... 24,949,325 shares of its common stock.  Funds under ...
(Date:12/24/2014)...  Advanced Medical Isotope Corporation ("AMIC") (OTCQB: ADMD), a ... development of brachytherapy devices and medical isotopes for ... has filed a de novo submission ... marketing clearance for its patented Y-90 RadioGel(TM) device ... Drug and Cosmetic Act (the "Act").  ...
Breaking Medicine Technology:Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3
... Kensey Nash Corporation (Nasdaq: KNSY ) ... Exemption (IDE) application to the U.S. Food and Drug ... unique biomaterials technology for treating articular cartilage defects of ... Cartilage Repair Device, which consists of a proprietary bi-phasic, ...
... MAP Pharmaceuticals, Inc. announced today that its initial Phase ... the potential treatment of children with asthma did not ... changes from baseline in nighttime and daytime composite symptom ... with placebo. AstraZeneca (NYSE: AZN ) ...
Cached Medicine Technology:Kensey Nash Announces IDE Submission for Cartilage Repair Device 2Kensey Nash Announces IDE Submission for Cartilage Repair Device 3Kensey Nash Announces IDE Submission for Cartilage Repair Device 4AstraZeneca's Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints 2
(Date:12/26/2014)... DW-InductionHeating.com (DaWei Induction Heating Co.) is ... developing, producing and marketing of a series of induction ... their new series of induction brazing equipments . ... induction brazing refers to the joining of ... and heat. The manager says that there are fundamental ...
(Date:12/25/2014)... December 26, 2014 The report ... to 2023” focuses on the current treatment landscape, ... the colorectal cancer market. Stivarga is a drug ... or rectal cancer. Boehringer Ingelheim is developing nintedanib ... treatment of refractory CRC in the US, Europe, ...
(Date:12/25/2014)... 2014 Recently, Dylan Queen, a famous ... released its collection of discounted prom dresses, most of ... senior spokesman of the company, the promotion is valid ... is to expand the UK market. , The prom ... colors, lengths, and styles: A-line strapless, empire strapless chiffon, ...
(Date:12/25/2014)... FL (PRWEB) December 25, 2014 When head ... find themselves in a frenzy to get rid of it ... But families in Coral Gables now have the solution right ... second salon clinic location, Lice Troopers provides full spectrum head ... the Coral Gable area, including Sunset, Key Biscayne, Brickell, Coconut ...
(Date:12/25/2014)... Among early stage breast cancer patients who undergo chemotherapy ... will eventually develop leukemia as a result of their ... from a review of more than 20,000 breast cancer ... that the risk for developing treatment-related leukemia, though low, ... "The frequency of bone marrow cancers such as leukemia ...
Breaking Medicine News(10 mins):Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... sex hormones, testosterone in men and estrogen in women, ... of cartilage tissue. The study suggests hormone replacement in ... beneficial in treating late stages of human osteoarthritis (OA) ... study appear in the April issue of Arthritis ...
... some viral infections fatal and others much less severe ... part of the variability can be attributed to differences ... Katze, presenting at the Society for General Microbiology,s spring ... be a powerful tool to allow treatments to be ...
... this may be why they are less likely to ... (HealthDay News) -- Preconceived attitudes about breast-feeding may explain ... women to breast-feed their infants, a new study shows. ... 2006 were ever breast-fed, compared with 77 percent of ...
... ARBOR, Mich. While radiation therapy is common after ... even among women for whom it would have clear ... from researchers at the University of Michigan Comprehensive Cancer ... for breast cancer, assessing whether they had lumpectomy or ...
... An important gene that normally protects the body against ... on the specific mutation that damages it, according to ... University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and ... mutations in a gene called PTEN. People who inherit ...
... may affect decision-making and self-control , MONDAY, March 29 ... (CRP) are associated with problems in executive thinking skills, ... study. , CRP is considered an indicator of inflammation. ... scans and were given tests of verbal memory, word ...
Cached Medicine News:Health News:Hormone replacement in joint fluid has potential regenerative effect 2Health News:Personalizing medicine to prevent pandemics 2Health News:Black Women in U.S. Comfortable With Formula Feeding 2Health News:Radiation after mastectomy underused, U-M study finds 2Health News:Study shows that mutations in 1 gene cause many cancers 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: